Table 3.

Oxidation products of Arachidonic Acid at baseline and change with PTX treatment

Lipid (lipid:precursor µmol/mol)	Baseline			Change from Baseline
	PTX (N=21)	Placebo (N=26)	p-value	PTX (N=21)	Placebo (N=26)	p-value
5-HETE	36.0[25.9,44.2]	32.9[22.6,47.8]	0.91	−6.0[−15.6,4.2]	+1.7[−9.6,10.1]	0.11
8-HETE	24.0[20.8,34.2]	22.9[18.5,28.6]	0.28	−4.6[−8.6,0.402]	+2.2[−1.1,9.5]	0.007
9-HETE	19.1[15.7,23.3]	16.4[13.5,21.5]	0.16	−3.0[−7.5,−0.917]	+1.3[−3.3,5.1]	0.019
11-HETE	28.5[24.1,36.7]	24.5[19.9,33.0]	0.13	−4.4[−8.1,1.083]	+2.0[−3.6,10.9]	0.015
12-HETE	36.0[30.9,57.3]	33.7[23.4,55.0]	0.24	−8.5[−17.5,−0.46]	+0.037[−15,29]	0.066
15-HETE	72.6[61.1,89.8]	71.5[58.1,86.6]	0.68	−13.9[−24.0,−9.9]	−0.36[−18,11.6]	0.063
AA (pmol/mL× 103)	512.7[459,579.5]	473.5[427.7,577]	0.28	+7.7[−21.4,46.0]	−12.1[−77.8,28]	0.23

Values presented as Median [P25, P75] with Wilcoxon rank sum tests